Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

Methylated DNA in Pancreatic Juice Distinguishes Patients With Pancreatic Cancer From Controls.

Majumder S, Raimondo M, Taylor WR, Yab TC, Berger CK, Dukek BA, Cao X, Foote PH, Wu CW, Devens ME, Mahoney DW, Smyrk TC, Pannala R, Chari ST, Vege SS, Topazian MD, Petersen BT, Levy MJ, Rajan E, Gleeson FC, Dayyeh BA, Nguyen CC, Faigel DO, Woodward TA, Wallace MB, Petersen G, Allawi HT, Lidgard GP, Kisiel JB, Ahlquist DA.

Clin Gastroenterol Hepatol. 2019 Jul 16. pii: S1542-3565(19)30750-5. doi: 10.1016/j.cgh.2019.07.017. [Epub ahead of print]

PMID:
31323382
2.

Novel Methylated DNA Markers Discriminate Advanced Neoplasia in Pancreatic Cysts: Marker Discovery, Tissue Validation, and Cyst Fluid Testing.

Majumder S, Taylor WR, Yab TC, Berger CK, Dukek BA, Cao X, Foote PH, Wu CW, Mahoney DW, Aslanian HR, Fernández-Del Castillo C, Doyle LA, Farrell JJ, Fisher WE, Lee LS, Lee YN, Park W, Rodrigues C, Gould Rothberg BE, Salem RR, Simeone DM, Urs S, Van Buren G, Smyrk TC, Allawi HT, Lidgard GP, Raimondo M, Chari ST, Kendrick ML, Kisiel JB, Topazian MD, Ahlquist DA.

Am J Gastroenterol. 2019 Jul 15. doi: 10.14309/ajg.0000000000000284. [Epub ahead of print]

PMID:
31306149
3.

Universal cancer screening: revolutionary, rational, and realizable.

Ahlquist DA.

NPJ Precis Oncol. 2018 Oct 29;2:23. doi: 10.1038/s41698-018-0066-x. eCollection 2018. Review.

4.

Response to Kosmidou et al.

Iyer PG, Ahlquist DA.

Am J Gastroenterol. 2018 Nov;113(11):1723. doi: 10.1038/s41395-018-0362-7. Epub 2018 Oct 17. No abstract available.

PMID:
30333549
5.

Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation.

Kisiel JB, Dukek BA, V S R Kanipakam R, Ghoz HM, Yab TC, Berger CK, Taylor WR, Foote PH, Giama NH, Onyirioha K, Abdallah MA, Burger KN, Slettedahl SW, Mahoney DW, Smyrk TC, Lewis JT, Giakoumopoulos M, Allawi HT, Lidgard GP, Roberts LR, Ahlquist DA.

Hepatology. 2019 Mar;69(3):1180-1192. doi: 10.1002/hep.30244. Epub 2019 Feb 5.

PMID:
30168613
6.

Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts.

Sawas T, Killcoyne S, Iyer PG, Wang KK, Smyrk TC, Kisiel JB, Qin Y, Ahlquist DA, Rustgi AK, Costa RJ, Gerstung M, Fitzgerald RC, Katzka DA; OCCAMS Consortium.

Gastroenterology. 2018 Dec;155(6):1720-1728.e4. doi: 10.1053/j.gastro.2018.08.036. Epub 2018 Aug 27.

7.

Highly Discriminant Methylated DNA Markers for the Non-endoscopic Detection of Barrett's Esophagus.

Iyer PG, Taylor WR, Johnson ML, Lansing RL, Maixner KA, Yab TC, Simonson JA, Devens ME, Slettedahl SW, Mahoney DW, Berger CK, Foote PH, Smyrk TC, Wang KK, Wolfsen HC, Ahlquist DA.

Am J Gastroenterol. 2018 Aug;113(8):1156-1166. doi: 10.1038/s41395-018-0107-7. Epub 2018 Jun 12.

PMID:
29891853
8.

Detection of Gastric Cancer with Novel Methylated DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma.

Anderson BW, Suh YS, Choi B, Lee HJ, Yab TC, Taylor WR, Dukek BA, Berger CK, Cao X, Foote PH, Devens ME, Boardman LA, Kisiel JB, Mahoney DW, Slettedahl SW, Allawi HT, Lidgard GP, Smyrk TC, Yang HK, Ahlquist DA.

Clin Cancer Res. 2018 Nov 15;24(22):5724-5734. doi: 10.1158/1078-0432.CCR-17-3364. Epub 2018 May 29.

9.

A Comprehensive Approach to Sequence-oriented IsomiR annotation (CASMIR): demonstration with IsomiR profiling in colorectal neoplasia.

Wu CW, Evans JM, Huang S, Mahoney DW, Dukek BA, Taylor WR, Yab TC, Smyrk TC, Jen J, Kisiel JB, Ahlquist DA.

BMC Genomics. 2018 May 25;19(1):401. doi: 10.1186/s12864-018-4794-7.

10.

Analysis of DNA Methylation at Specific Loci in Stool Samples Detects Colorectal Cancer and High-Grade Dysplasia in Patients With Inflammatory Bowel Disease.

Kisiel JB, Klepp P, Allawi HT, Taylor WR, Giakoumopoulos M, Sander T, Yab TC, Moum BA, Lidgard GP, Brackmann S, Mahoney DW, Roseth A, Ahlquist DA.

Clin Gastroenterol Hepatol. 2019 Apr;17(5):914-921.e5. doi: 10.1016/j.cgh.2018.05.004. Epub 2018 May 15.

PMID:
29775793
11.

Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study.

Klepp P, Kisiel JB, Småstuen MC, Røseth A, Andersen SN, Vatn MH, Ahlquist DA, Moum BA, Brackmann S.

Scand J Gastroenterol. 2018 Mar;53(3):273-278. doi: 10.1080/00365521.2018.1424935. Epub 2018 Jan 9.

PMID:
29313389
12.

Comment on "Fecal occult blood versus DNA testing: indirect comparison in a colorectal cancer screening population".

Ahlquist DA.

Clin Epidemiol. 2017 Aug 28;9:435-438. doi: 10.2147/CLEP.S148780. eCollection 2017. No abstract available.

13.

Novel Approach to Fecal Occult Blood Testing by Assay of Erythrocyte-Specific microRNA Markers.

Wu CW, Cao X, Berger CK, Foote PH, Mahoney DW, Simonson JA, Anderson BW, Yab TC, Taylor WR, Boardman LA, Kisiel JB, Ahlquist DA.

Dig Dis Sci. 2017 Aug;62(8):1985-1994. doi: 10.1007/s10620-017-4627-6. Epub 2017 Jun 28.

14.

Costs associated with Barrett's esophagus screening in the community: an economic analysis of a prospective randomized controlled trial of sedated versus hospital unsedated versus mobile community unsedated endoscopy.

Moriarty JP, Shah ND, Rubenstein JH, Blevins CH, Johnson M, Katzka DA, Wang KK, Wongkeesong LM, Ahlquist DA, Iyer PG.

Gastrointest Endosc. 2018 Jan;87(1):88-94.e2. doi: 10.1016/j.gie.2017.04.019. Epub 2017 Apr 25.

15.

Time Lapse to Colorectal Cancer: Telomere Dynamics Define the Malignant Potential of Polyps.

Druliner BR, Ruan X, Johnson R, Grill D, O'Brien D, Lai TP, Rashtak S, Felmlee-Devine D, Washechek-Aletto J, Malykh A, Smyrk T, Oberg A, Liu H, Shay JW, Ahlquist DA, Boardman LA.

Clin Transl Gastroenterol. 2017 Apr 13;8(4):e88. doi: 10.1038/ctg.2017.16. No abstract available.

16.

The Case for a Multitarget Stool DNA Test: A Closer Look at the Cost Effectiveness Model.

Itzkowitz SH, Ahlquist DA.

Gastroenterology. 2017 May;152(6):1620-1621. doi: 10.1053/j.gastro.2016.11.058. Epub 2017 Apr 3. No abstract available.

PMID:
28384447
17.

Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue.

Levin TR, Corley DA, Jensen CD, Marks AR, Zhao WK, Zebrowski AM, Quinn VP, Browne LW, Taylor WR, Ahlquist DA, Lidgard GP, Berger BM.

Dig Dis Sci. 2017 Mar;62(3):678-688. doi: 10.1007/s10620-016-4433-6. Epub 2017 Jan 2.

18.

Long-term Follow-up of Patients Having False-Positive Multitarget Stool DNA Tests after Negative Screening Colonoscopy: The LONG-HAUL Cohort Study.

Cotter TG, Burger KN, Devens ME, Simonson JA, Lowrie KL, Heigh RI, Mahoney DW, Johnson DH, Ahlquist DA, Kisiel JB.

Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):614-621. doi: 10.1158/1055-9965.EPI-16-0800. Epub 2016 Dec 20.

19.

Multitarget stool DNA test: clinical performance and impact on yield and quality of colonoscopy for colorectal cancer screening.

Johnson DH, Kisiel JB, Burger KN, Mahoney DW, Devens ME, Ahlquist DA, Sweetser S.

Gastrointest Endosc. 2017 Mar;85(3):657-665.e1. doi: 10.1016/j.gie.2016.11.012. Epub 2016 Nov 21.

20.

Stool DNA Analysis is Cost-Effective for Colorectal Cancer Surveillance in Patients With Ulcerative Colitis.

Kisiel JB, Konijeti GG, Piscitello AJ, Chandra T, Goss TF, Ahlquist DA, Farraye FA, Ananthakrishnan AN.

Clin Gastroenterol Hepatol. 2016 Dec;14(12):1778-1787.e8. doi: 10.1016/j.cgh.2016.07.018. Epub 2016 Jul 25. Erratum in: Clin Gastroenterol Hepatol. 2017 Apr;15(4):609.

21.

Shifts in the Fecal Microbiota Associated with Adenomatous Polyps.

Hale VL, Chen J, Johnson S, Harrington SC, Yab TC, Smyrk TC, Nelson H, Boardman LA, Druliner BR, Levin TR, Rex DK, Ahnen DJ, Lance P, Ahlquist DA, Chia N.

Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):85-94. doi: 10.1158/1055-9965.EPI-16-0337. Epub 2016 Sep 26.

22.

Time Lapse to Colorectal Cancer: Telomere Dynamics Define the Malignant Potential of Polyps.

Druliner BR, Ruan X, Johnson R, Grill D, O'Brien D, Lai TP, Rashtak S, Felmlee-Devine D, Washechek-Aletto J, Malykh A, Smyrk T, Oberg A, Liu H, Shay JW, Ahlquist DA, Boardman LA.

Clin Transl Gastroenterol. 2016 Sep 1;7(9):e188. doi: 10.1038/ctg.2016.48.

23.

Systematic review with meta-analysis: prevalent vs. incident oesophageal adenocarcinoma and high-grade dysplasia in Barrett's oesophagus.

Visrodia K, Singh S, Krishnamoorthi R, Ahlquist DA, Wang KK, Iyer PG, Katzka DA.

Aliment Pharmacol Ther. 2016 Oct;44(8):775-84. doi: 10.1111/apt.13783. Epub 2016 Aug 26. Review.

24.

Molecular Detection of Gastrointestinal Neoplasia: Innovations in Early Detection and Screening.

Anderson BW, Ahlquist DA.

Gastroenterol Clin North Am. 2016 Sep;45(3):529-42. doi: 10.1016/j.gtc.2016.04.009. Review.

PMID:
27546847
25.

Colorectal Adenomas.

Itzkowitz SH, Ahlquist DA.

N Engl J Med. 2016 Jul 28;375(4):388-9. doi: 10.1056/NEJMc1604867. No abstract available.

PMID:
27464215
26.

Multi-Target Stool DNA Test: Is the Future Here?

Sweetser S, Ahlquist DA.

Curr Gastroenterol Rep. 2016 Jun;18(6):30. doi: 10.1007/s11894-016-0510-4. Review.

PMID:
27165404
27.

DNA Methylation and Mutation of Small Colonic Neoplasms in Ulcerative Colitis and Crohn's Colitis: Implications for Surveillance.

Johnson DH, Taylor WR, Aboelsoud MM, Foote PH, Yab TC, Cao X, Smyrk TC, Loftus EV Jr, Mahoney DW, Ahlquist DA, Kisiel JB.

Inflamm Bowel Dis. 2016 Jul;22(7):1559-67. doi: 10.1097/MIB.0000000000000795.

28.

Magnetophoretic-based microfluidic device for DNA Concentration.

Shim S, Shim J, Taylor WR, Kosari F, Vasmatzis G, Ahlquist DA, Bashir R.

Biomed Microdevices. 2016 Apr;18(2):28. doi: 10.1007/s10544-016-0051-5.

PMID:
26899965
29.

Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis.

Visrodia K, Singh S, Krishnamoorthi R, Ahlquist DA, Wang KK, Iyer PG, Katzka DA.

Gastroenterology. 2016 Mar;150(3):599-607.e7; quiz e14-5. doi: 10.1053/j.gastro.2015.11.040. Epub 2015 Nov 24. Review.

30.

Molecular detection of pancreatic neoplasia: Current status and future promise.

Majumder S, Chari ST, Ahlquist DA.

World J Gastroenterol. 2015 Oct 28;21(40):11387-95. doi: 10.3748/wjg.v21.i40.11387. Review.

31.

Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People.

Redwood DG, Asay ED, Blake ID, Sacco PE, Christensen CM, Sacco FD, Tiesinga JJ, Devens ME, Alberts SR, Mahoney DW, Yab TC, Foote PH, Smyrk TC, Provost EM, Ahlquist DA.

Mayo Clin Proc. 2016 Jan;91(1):61-70. doi: 10.1016/j.mayocp.2015.10.008. Epub 2015 Oct 28.

32.

Stool DNA testing: a new, noninvasive option for colorectal cancer screening.

Ahlquist DA.

Clin Adv Hematol Oncol. 2015 Jul;13(7):432-4. No abstract available.

PMID:
26353038
33.

Endoscopic overestimation of colorectal polyp size.

Anderson BW, Smyrk TC, Anderson KS, Mahoney DW, Devens ME, Sweetser SR, Kisiel JB, Ahlquist DA.

Gastrointest Endosc. 2016 Jan;83(1):201-8. doi: 10.1016/j.gie.2015.06.058. Epub 2015 Aug 28.

PMID:
26318830
34.

Fecal Recovery of Ingested Cellular DNA: Implications for Noninvasive Detection of Upper Gastrointestinal Neoplasms.

Strauss BB, Yab TC, O'Connor HM, Taylor WR, Mahoney DW, Simonson JA, Christensen J, Chari ST, Ahlquist DA.

Dig Dis Sci. 2016 Jan;61(1):117-25. doi: 10.1007/s10620-015-3845-z. Epub 2015 Aug 22.

PMID:
26297132
35.

New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice.

Kisiel JB, Raimondo M, Taylor WR, Yab TC, Mahoney DW, Sun Z, Middha S, Baheti S, Zou H, Smyrk TC, Boardman LA, Petersen GM, Ahlquist DA.

Clin Cancer Res. 2015 Oct 1;21(19):4473-81. doi: 10.1158/1078-0432.CCR-14-2469. Epub 2015 May 28.

36.

Molecular markers for colorectal cancer screening.

Dickinson BT, Kisiel J, Ahlquist DA, Grady WM.

Gut. 2015 Sep;64(9):1485-94. doi: 10.1136/gutjnl-2014-308075. Epub 2015 May 20. Review.

37.

Early detection of sporadic pancreatic cancer: summative review.

Chari ST, Kelly K, Hollingsworth MA, Thayer SP, Ahlquist DA, Andersen DK, Batra SK, Brentnall TA, Canto M, Cleeter DF, Firpo MA, Gambhir SS, Go VL, Hines OJ, Kenner BJ, Klimstra DS, Lerch MM, Levy MJ, Maitra A, Mulvihill SJ, Petersen GM, Rhim AD, Simeone DM, Srivastava S, Tanaka M, Vinik AI, Wong D.

Pancreas. 2015 Jul;44(5):693-712. doi: 10.1097/MPA.0000000000000368. Review.

38.

Nanopore-based assay for detection of methylation in double-stranded DNA fragments.

Shim J, Kim Y, Humphreys GI, Nardulli AM, Kosari F, Vasmatzis G, Taylor WR, Ahlquist DA, Myong S, Bashir R.

ACS Nano. 2015 Jan 27;9(1):290-300. doi: 10.1021/nn5045596. Epub 2015 Jan 15.

PMID:
25569824
39.

Multi-target stool DNA test: a new high bar for noninvasive screening.

Ahlquist DA.

Dig Dis Sci. 2015 Mar;60(3):623-33. doi: 10.1007/s10620-014-3451-5. Epub 2014 Dec 10. Review.

PMID:
25492503
40.

Methylated Bone Morphogenetic Protein 3 (BMP3) Gene: Evaluation of Tumor Suppressor Function and Biomarker Potential in Biliary Cancer.

Kisiel JB, Li J, Zou H, Oseini AM, Strauss BB, Gulaid KH, Moser CD, Aderca I, Ahlquist DA, Roberts LR, Shire AM.

J Mol Biomark Diagn. 2013 Aug 3;4(145):1000145.

41.

Stool methylated DNA markers decrease following colorectal cancer resection--implications for surveillance.

Kisiel JB, Yab TC, Taylor WR, Mahoney DW, Ahlquist DA.

Dig Dis Sci. 2014 Aug;59(8):1764-7. doi: 10.1007/s10620-014-3265-5. Epub 2014 Jul 4.

42.

Patient perceptions of stool DNA testing for pan-digestive cancer screening: a survey questionnaire.

Yang D, Hillman SL, Harris AM, Sinicrope PS, Devens ME, Ahlquist DA.

World J Gastroenterol. 2014 May 7;20(17):4972-9. doi: 10.3748/wjg.v20.i17.4972.

43.

Detection rate and outcome of colonic serrated epithelial changes in patients with ulcerative colitis or Crohn's colitis.

Johnson DH, Khanna S, Smyrk TC, Loftus EV Jr, Anderson KS, Mahoney DW, Ahlquist DA, Kisiel JB.

Aliment Pharmacol Ther. 2014 Jun;39(12):1408-17. doi: 10.1111/apt.12774. Epub 2014 Apr 30.

44.

Multitarget stool DNA testing for colorectal-cancer screening.

Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, Ahlquist DA, Berger BM.

N Engl J Med. 2014 Apr 3;370(14):1287-97. doi: 10.1056/NEJMoa1311194. Epub 2014 Mar 19.

45.

Detection of colorectal serrated polyps by stool DNA testing: comparison with fecal immunochemical testing for occult blood (FIT).

Heigh RI, Yab TC, Taylor WR, Hussain FT, Smyrk TC, Mahoney DW, Domanico MJ, Berger BM, Lidgard GP, Ahlquist DA.

PLoS One. 2014 Jan 20;9(1):e85659. doi: 10.1371/journal.pone.0085659. eCollection 2014.

46.

Stool DNA testing for cancer surveillance in inflammatory bowel disease: an early view.

Kisiel JB, Ahlquist DA.

Therap Adv Gastroenterol. 2013 Sep;6(5):371-80. doi: 10.1177/1756283X13487941.

47.

Methylated eyes absent 4 (EYA4) gene promotor in non-neoplastic mucosa of ulcerative colitis patients with colorectal cancer: evidence for a field effect.

Kisiel JB, Garrity-Park MM, Taylor WR, Smyrk TC, Ahlquist DA.

Inflamm Bowel Dis. 2013 Sep;19(10):2079-83. doi: 10.1097/MIB.0b013e31829b3f4d.

48.

Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia.

Lidgard GP, Domanico MJ, Bruinsma JJ, Light J, Gagrat ZD, Oldham-Haltom RL, Fourrier KD, Allawi H, Yab TC, Taylor WR, Simonson JA, Devens M, Heigh RI, Ahlquist DA, Berger BM.

Clin Gastroenterol Hepatol. 2013 Oct;11(10):1313-8. doi: 10.1016/j.cgh.2013.04.023. Epub 2013 Apr 29.

PMID:
23639600
49.

Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease.

Kisiel JB, Yab TC, Nazer Hussain FT, Taylor WR, Garrity-Park MM, Sandborn WJ, Loftus EV, Wolff BG, Smyrk TC, Itzkowitz SH, Rubin DT, Zou H, Mahoney DW, Ahlquist DA.

Aliment Pharmacol Ther. 2013 Mar;37(5):546-54. doi: 10.1111/apt.12218. Epub 2013 Jan 24.

50.

Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates.

Berger BM, Ahlquist DA.

Pathology. 2012 Feb;44(2):80-8. doi: 10.1097/PAT.0b013e3283502fdf. Review.

PMID:
22198259

Supplemental Content

Loading ...
Support Center